We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Umecrine Cognition Raises New Funds to Support Clinical Development

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Umecrine Cognition AB has announced it has completed a private financing round that will support the clinical development of its lead drug candidate for HE in liver disease patients. New investors, Fort Knox Förvaring AB, Partnerinvest Övre Norrland AB and Norrlandsfonden join founder investor Karolinska Development in this new financing round.

The new funds will be used by Umecrine Cognition to conduct a Phase I (first in human) clinical trial with the company’s oral drug candidate GR3027 in 58 healthy volunteers to assess safety, tolerability, and pharmacokinetics, and to establish clinical proof-of-principle with regard to the mechanism of action of GR3027. First patients have been enrolled at a clinical centre in Sweden, and results from the study are expected in H2 2016.

HE is a frequent neurological complication and one of the most debilitating manifestations of liver disease affecting millions around the world. Caused by liver insufficiency, HE leads to a general depression of the central nervous system with clinical manifestations ranging from mild cognitive impairment to deep coma. This severely affects the lives of patients and their caregivers. The cognitive impairment associated with cirrhosis can also result in the utilization of more health care resources for adults than other manifestations of liver disease.

There are no known treatments on the market that directly target the neurological cause of HE. Umecrine Cognition’s lead candidate GR3027 is a GABAA receptor modulating steroid antagonist (GAMSA) designed to antagonize GABAA receptor activation by endogenous neuroactive steroids. The enhanced signaling from GABAA receptors is a key driver for the neurological symptoms associated with HE. In preclinical animal models, GR3027 normalizes key neurological symptoms associated with HE.

Preclinical safety and toxicity studies suggest that GR3027 is a safe and well-tolerated drug. Magnus Doverskog, CEO of Umecrine Cognition, comments: “This announcement represents a significant milestone for Umecrine Cognition. Our short-term financial aims are to finalize the investor consortium with qualified investors that will take the company through to clinical proof-of-concept, which is primary efficacy data of GR3027 in patients with HE. We now have the first part of a strong investor consortium in place.

I am very pleased to welcome Fort Knox Förvaring AB, Partnerinvest Övre Norrland AB and Norrlandsfonden onboard, and also by the continued support from Karolinska Development. “We now enter clinical development with GR3027, a drug candidate that has show unprecedented preclinical data in a therapeutic area where the treatment options today are very limited. The clinical development approach is to first confirm the treatment principle of GR3027 in this Phase I trial with healthy volunteers before advancing to HE patients in subsequent clinical studies.”